Ucb

UCB, a Pharmaceutical Preparation Manufacturing company headquartered in Belgium, reported total emissions of approximately 872 million kg CO2e in 2025. This includes about 22.19 million kg CO2e from Scope 1, 15 thousand kg CO2e from market-based Scope 2, and 849.80 million kg CO2e from Scope 3 emissions.

In 2024, UCB's total emissions were approximately 790.86 million kg CO2e, comprising around 21.72 million kg CO2e from Scope 1, 5 thousand kg CO2e from market-based Scope 2, and 769.14 million kg CO2e from Scope 3.

For 2023, the company's total emissions were about 85.33 million kg CO2e, with Scope 1 emissions at approximately 20.55 million kg CO2e, market-based Scope 2 emissions at roughly 1.62 million kg CO2e, and Scope 3 emissions around 63.17 million kg CO2e.

UCB has set several ambitious climate commitments. The company has validated Science Based Targets initiative (SBTi) targets to reach net-zero greenhouse gas emissions across its value chain by 2045.

Near-term SBTi targets include:

• A 73% reduction in absolute Scope 1 and 2 GHG emissions by 2030, from a 2019 base year.
• A 48% reduction in absolute Scope 3 GHG emissions (from fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, upstream leased assets, and end-of-life treatment of sold products) by 2030, from a 2019 base year.
• Ensuring that 80% of its suppliers, by emissions covering purchased goods and services, have science-based targets by 2028.

Long-term SBTi targets (by 2045 from a 2019 base year) include:

• A 90% reduction in absolute Scope 1 and 2 GHG emissions.
• A 90% reduction in absolute Scope 3 GHG emissions (from purchased goods and services, fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, upstream leased assets, and end-of-life treatment of sold products).